Table 3 Incidence rate of malignancies in early RA patients according to bDMARD use
Type of malignancy | bDMARD ever-user (n = 714) | bDMARD nonuser (n = 11,683) | Standardized incidence rate | ||
|---|---|---|---|---|---|
N | IRa (95% CI) | N | IRa (95% CI) | SIR (95% CI)b | |
All malignancies | 20 | 81.5 (45.8–117.2) | 705 | 180.1 (166.8–193.4) | 0.5 (0.3–0.7) |
 Lip, oral cavity, and pharynx | 0 | – | 9 | 2.3 (0.8–3.8) | – |
 Esophagus | 0 | – | 3 | 0.8 –(0.1–1.6) | – |
 Stomach | 3 | 12.2 (1.6–26.0) | 58 | 14.8 (11.0–18.6) | 0.8 (0.2–2.4) |
 Colon and rectum | 1 | 4.07 (3.9–12.0) | 83 | 21.2 (16.6–25.8) | 0.2 (0.0–1.1) |
 Liver | 1 | 4.07 (3.9–12.0) | 51 | 13.0 (9.5–16.6) | 0.3 (0.01–1.7) |
 Gallbladder | – | – | 10 | 2.6 (1.0–4.1) | – |
 Pancreas | 1 | 4.07 (3.9–12.0) | 49 | 12.5 (9.0–16.0) | 0.3 (0.01–1.8) |
 Larynx | 0 | – | 5 | 1.3 (0.2–2.4) | – |
 Lung | 3 | 12.2 (1.6–26.0) | 57 | 14.6 (10.8–18.3) | 0.8 (0.2–2.5) |
 Breast | 3 | 12.2 (1.6–26.0) | 36 | 9.2 (6.2–12.2) | 1.3 (0.3–3.9) |
 Cervix uteri | 0 | – | 17 | 4.3 (2.3–6.4) | – |
 Corpus uteri | 0 | – | 4 | 1.0 (0.0–2.0) | – |
 Ovary | 0 | – | 13 | 3.3 (1.5–5.1) | – |
 Prostate | 0 | – | 47 | 12.0 (8.6–15.4) | – |
 Testis | 0 | – | 3 | 0.8 (0.1–1.6) | – |
 Kidney | 0 | – | 8 | 2.0 (0.6–3.5) | – |
 Bladder | 0 | – | 14 | 3.6 (1.7–5.5) | – |
 Brain and CNS | 0 | – | 5 | 1.3 (0.2–2.4) | – |
 Thyroid | 1 | 4.1 (3.9–12.0) | 86 | 22.0 (17.3–26.6) | 0.2 (0.0–1.03) |
Hematologic malignancy | 3 | 12.2 (1.6–26.0) | 18 | 4.6 (2.5–6.7) | 2.7 (0.6–7.8) |
 Hodgkin lymphoma | 0 | – | 1 | 0.3 (0.2–0.8) | – |
 Non-Hodgkin lymphoma | 2 | 8.2 (3.1–19.4) | 11 | 2.8 (1.1–4.5) | 2.9 (0.4–10.5) |
 Multiple myeloma | 0 | – | 1 | 0.3 (0.2–0.8) | – |
 Leukemia | 1 | 4.1 (3.9–12.0) | 5 | 1.3 (0.2–2.4) | 3.2 (0.1–18.0) |
Others | 4 | 16.3 (0.3–32.3) | 129 | 33.0 (27.3–38.6) | 0.5 (0.1–1.3) |